Skip to main content

GSK lifts 2022 view after third quarter sales of $8.99 billion beat forecasts

The British pharma major posted sales of 7.83 billion pounds ($8.99 billion) for the third quarter, up from GBP6.63 billion the year prior, and beating a company-provided consensus of GBP7.32 billion.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.